1. Scrip
  2. >>New Products

FDA Backs Novartis MS Pill Mayzent With Broad Label

 
• By Kevin Grogan

Mayzent is the first oral therapy proven to delay progression in patients with secondary progressive multiple sclerosis and Novartis pharma chief Paul Hudson tells Scrip its $88,500 list price will not affect access.

Wall
Mayzent approval is a breakthrough for SPMS • Source: Shutterstock

Novartis AG has won FDA approval for its eagerly anticipated multiple sclerosis drug Mayzent and won big, with the agency granting the green light for the therapy to be used across the spectrum for patients with relapsing forms of the neurological disease.

The thumbs-up from the FDA means that Mayzent (siponimod) is now the first oral treatment specifically indicated for active secondary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 
• By Jessica Merrill

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

More from Scrip

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.